Interim Management Statement

RNS Number : 5530J

Intl. Biotechnology Trust PLC

17 July 2013

 



INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the "Company")

Interim Management Statement (Unaudited)

For the three months ended 31 May 2013

Introduction

The Board of International Biotechnology Trust plc is pleased to announce its Interim Management Statement ("IMS") in accordance with the requirements of the UK Listing Authority's Disclosure and Transparency Rules. The IMS covers the three month period ended 31 May 2013, together with relevant information up to the date of this announcement.

Investment Objective

The Company's investment objective is to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies that are either quoted or unquoted and possess the potential for high growth. The Company invests in companies whose shares are considered to have good prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. 

Material Events

On 12 April 2013 the Company released its Half Yearly Financial Report announcement for the six months ended 28 February 2013.  As before, there was no dividend declared. 

During the three months ended 31 May 2013, the Company bought back a total of 300,000 Ordinary 25p shares to be held in treasury.  No shares were cancelled from treasury during the period.  Following this buyback, the Company has 55,157,663 Ordinary 25p shares in issue and 600,000 shares in treasury as at the date of this announcement.

During the period ended 31 May 2013, and up to the date of this announcement, the Company made an announcement regarding changes to the valuation of portfolio companies.  The unquoted companies in the portfolio are revalued on an ongoing basis as and when information on their performance or rounds of financing becomes available, and we would therefore refer you to the London Stock Exchange website, www.londonstockexchange.com, where copies of all announcements relating to changes to portfolio companies are available for your review.

No other material events took place in the period that had any significant impact on the financial position of the Company. 

Material Transactions

No material transactions, other than those mentioned above, took place in the period that had any significant impact on the financial position of the Company.

Company Statistics*

	31 May 2013	28 February 2013
Total Net Asset Value	£163.8m	£128.9m
Net Asset Value (NAV) per Ordinary Share	297.0p	232.0p
Share Price	258.5p	204.5p
Share Price Premium/(Discount) to NAV	(13.0)%	(15.3)%
Total Value of Unquoted Investments	£25.8m	£20.6m
Total Number of Portfolio Holdings	70	70
Cash	1% NAV	7% NAV
Cash Committed and Reserved to Unquoted Investments	(4.5)% NAV	(5.4)% NAV

*Data Source for all Statistical Data: HSBC/SV Life Sciences

Cumulative Performance to 31 May 2013**

Performance Over	1 mth	1 year	3 years	5 years
NAV per share (Cum)	5.8%	35.7%	76.6%	118.0%
Share Price	4.2%	40.3%	87.0%	122.8%
NASDAQ Biotech Index Return (Sterling adjusted)	6.4%	48.2%	112.6%	198.5%
FTSE All-Share Index (Total Return)	2.9%	30.7%	46.5%	38.6%

**Data Source for all Performance Data: Bloomberg

Portfolio Information as at 31 May 2013

Ten Largest Investments 

Investment	Weighting (% NAV)	Country
Gilead	6.9%	USA
Amgen	6.6%	USA
Celgene	6.1%	USA
Alexion	5.0%	USA
Onyx	4.2%	USA
Biogen	3.9%	USA
Aptiv…	3.6%	USA
Insulet	2.8%	USA
Regeneron	2.7%	USA
Achillion	2.4%	USA

^… Unquoted company investment.

Sector Allocation (Plus Cash Committed)  

Sector	Weighting (% NAV)
Therapeutics	74%
Life Sciences, Tools, Diagnostics & Services	11%
Medical Devices	7%
Specialty Pharma	7%
Cash	1%

Commitments and estimated reserves for further investments in unquoted investments (5)%

General Company Information

SEDOL Code	045593
Sector	Sector Specialist - Biotechnology
Launch Date	May 1994
Financial Year End	31 August
Next Continuation Vote	2013 AGM

A copy of this IMS is available on the Company's website at: www.ibtplc.com

Enquiries:

Kate Bingham/Ailsa Craig

SV Life Sciences Managers LLP          

Investment Manager 

Tel: [phone]

Rhona Gregg

BNP Paribas Secretarial Services Limited

Company Secretary

Tel: [phone]

17 JULY 2013

 

END

 

 

IMSGGUWAMUPWGWM